Abstract
Cedazuridine is a small molecule inhibitor of cytidine deaminase that is used as a pharmacoenhancer of decitabine to increase oral bioavailability of this DNA methylase inhibitor treatment of myelodysplastic syndromes. The combination of oral decitabine and cedazuridine is associated with a low rate of minor serum enzyme elevations during therapy that is usually attributed to decitabine. The oral combination has not been linked to cases of clinically apparent liver injury.
摘要
塞扎胞苷是一种胞苷脱氨酶小分子抑制剂，用作地西他滨的药物增强剂，以提高这种用于治疗骨髓增生异常综合征的DNA甲基化酶抑制剂的口服生物利用度。口服地西他滨和塞扎胞苷的联合用药在治疗期间血清酶轻度升高的发生率较低，这通常归因于地西他滨。口服联合用药尚未与临床明显肝损伤病例相关联。
相似文献
2
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.地西他滨与西扎珠苷口服固定剂量复方制剂治疗骨髓增生异常综合征：一项多中心、开放标签、剂量递增的1期研究。
Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.
3
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.口服地西他滨-西达赛布与静脉注射地西他滨治疗骨髓增生异常综合征和慢性粒单核细胞白血病（ASCERTAIN）：一项注册、随机、交叉、药代动力学、3 期研究。
Lancet Haematol. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1.
4
Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report.接受地西他滨/西扎珠苷治疗的慢性粒单核细胞白血病患者出现可逆性心肌病：一例报告
Cardiooncology. 2023 Jan 18;9(1):4. doi: 10.1186/s40959-023-00153-6.
5
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.西达苷/地西他滨：在髓系恶性肿瘤中从临床前到临床开发。
Blood Adv. 2021 Apr 27;5(8):2264-2271. doi: 10.1182/bloodadvances.2020002929.
6
Decitabine/Cedazuridine: First Approval.地西他滨/西达佐嘧啶：首次批准。
Drugs. 2020 Sep;80(13):1373-1378. doi: 10.1007/s40265-020-01389-7.
7
Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.西达本胺/地西他滨在骨髓增生异常综合征和慢性粒单核细胞白血病治疗中的作用。
Future Oncol. 2021 Jun;17(16):2077-2087. doi: 10.2217/fon-2020-1210. Epub 2021 Mar 12.
8
Novel agents for myelodysplastic syndromes.骨髓增生异常综合征的新型药物。
J Oncol Pharm Pract. 2021 Dec;27(8):1982-1992. doi: 10.1177/10781552211037993. Epub 2021 Sep 24.
9
[New treatment for myelodysplastic syndromes: luspatercept and oral hypomethylating agents].骨髓增生异常综合征的新疗法：罗特西普与口服低甲基化药物
Rinsho Ketsueki. 2022;63(9):1099-1106. doi: 10.11406/rinketsu.63.1099.
10
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.地西他滨联合 Cedazuridine 和 Venetoclax 治疗高危骨髓增生异常综合征或慢性粒单核细胞白血病患者的单中心 1/2 期研究。
Lancet Haematol. 2024 Mar;11(3):e186-e195. doi: 10.1016/S2352-3026(23)00367-8. Epub 2024 Feb 2.
Zotero 插件